If you’re on the hunt for stocks to watch today, Unity Biotechnology, Inc. (NASDAQ:UBX) is a stock to give close attention to. The company shares are trading 0.87% or 0.07 points down from last closing price of $8.08, reaching $8.01 at last check. The UBX share price has dropped in 1 of the last 5 days and is down -7.55% over the past week. It will be exciting to see whether the stock manages to continue decreasing or take a minor break for the next few days. The move came on solid volume too with far more shares changing hands than in a normal session. Trading activity as of this writing strengthened by 449,822 shares, and in total 673922 shares valued at $5.398 million were seen changing hands compared with 224100 shares valued at $1.811 million recorded at the previous session. You should take into consideration that a greater volume on lower prices causes the situation where nobody wants to continue with their long position and wants to exit from the UBX stock.
Unity Biotechnology, Inc. (UBX) shares have notched a 3-month decline of about -7.55%, but has still tumbled -50.31% year to date. By comparison, the stock sank -55.58% over the past 12 months, while it jumped 23.74% over the 1 month. The company’s market cap is around $331.52M, with its short interest ratio standing at 16.65%.
In the current trading session for UBX, the stock witnessed two major price actions, it rose to a high of $8.37 and was down as much as $7.66 at one point. The high recorded is very low when compared to their 52-week high which is $5.61. The 52-week high is now at -67.96 distance from current price. Their recent low of $24.56 represents a 40.29% recovery. This data is quite important for investors who look to benefit from the recent rise of the company’s stock. The price target currently for UBX is $21.6, this is below the recent high that the stock attained. Taking a look at the overall sentimental views of financial analysts, the trading pattern of this stock recently is very clear.
UBX‘s last price was down -19.46% as compared to the average trading price of 50 days recorded at $9.95 while enlarging the period to 200 trading days, the average closing price was $7.18. At present, there are 41.03 million in the total number of common shares owned by the public and among those 34.2 million shares have been available to trade. The percentage of shares being held by the company management was 8.2% while institutions stake was 72.8%. The company has generated negative returns on equity over the last 12 months (-53.9%). It managed to keep its gross profit margin at 0% over the past 12 months.
When assessing the full upside of the UBX stock, there is another set of technicals that should be looked into and considered. Its 22.78% gain from moving average of $6.52 has brought about a positive sentiment when calculated over the last 20 days. The market has allocated a beta of 0 to the stock. With the beta been less than one, this implies that the company shares are theoretically less volatile than the market, something that the traders definitely are keeping an eye on.
Most of the analysts surveyed by Thomson/First Call think quite highly of Unity Biotechnology, Inc. — 3 analysts rate the stock as a buy with another 0 rating it strong buy. There are 0 analysts who maintain a hold rating for the stock, with 0 giving it a sell rating. Analysts arrived at a 12-month price target of $17.5 on shares of Unity Biotechnology, Inc. (NASDAQ:UBX), which corresponds to 125.52% upside potential than its current market price of $8.01 and implies potential despite the recent drop in the price. However, their current target price has fallen from $22.6667 a month ago and is down handily from the consensus target of $26 a quarter ago.
Let’s briefly check the hedge fund interest towards UBX stock. Susquehanna International Group LLP trimmed position in the company after it dumped -246.7% or -11,898 shares of its common stock. The hedge fund now owns 17,454 shares worth $139,807, SEC documents show. Citadel Advisors LLC shored up assets in the stock as 43421.86 shares have been purchased, increasing its stake by 449% to 238,386 shares which are currently valued at $1,909,472. In addition, Morgan Stanley recently reported that it now owns 112,621 shares making a total of $902,094 based on the recent price. This refelects a change of -74.9% in their ownership.